论文部分内容阅读
目的：探讨瑞舒伐他汀、氯沙坦联合对氧化低密度脂蛋白（ox-LDL）诱导的人单核-巨噬细胞肝X受体（LXR）表达的影响及可能的机制。方法分离并培养人单核细胞，转化为巨噬细胞。据实验要求设置空白对照组、ox-LDL模型对照组、氯沙坦组、瑞舒伐他汀组、瑞舒伐他汀联合氯沙坦组，反转录聚合酶链反应（RT-PCR）法测定各组LXR的mRNA的表达。结果与空白对照组比较，ox-LDL模型对照组LXRmRNA表达明显降低（P＜0．05）；氯沙坦组与ox-LDL模型对照组比较，LXRmRNA表达显著增加（P＜0．05）；瑞舒伐他汀组与OX-LDL模型对照组比较，LXR mRNA表达显著增加（P＜0．05）；瑞舒伐他汀联合氯沙坦组与ox-LDL模型对照组比较， LXR mRNA表达显著增加（P＜0．05），且高于单药组（P＜0．05）。结论瑞舒伐他汀、氯沙坦均可上调LXR的表达，而瑞舒伐他汀与氯沙坦以适宜剂量联合后，LXR的表达增高比单独用药更为显著。“,”Objective To determine the effects and putative mechanisms of rosuvastatin plus losartan on liver X receptor (LXR) expression in cultured human monocyte-macrophages induced by oxidized low-density lipoprotein (ox-LDL). Methods Human monocytes were isolated and transformed to macrophages, which were assigned to control group, ox-LDL group, losartan group, rosuvastatin group and losartan plus rosuvastatin group. The expression of LXR mRNA was assayed by using reverse transcriptase polymerase chain reaction. Results Compared with control group, the expression of LXR was atenuated in the ox-LDL group (P<0.05). Losartan group yielded higher levels of LXR ex-pression compared with ox-LDL group (P<0.05). Treatment with rosuvastatin resulted in a marked increase in LXR ex-pression (P<0.05) compared with ox-LDL group. The losartan plus rosuvastatin group was associated with markedly higher levels of LXR expression compared with the remaining groups (all P<0.05). Conclusion Losartan and rosu-vastatin, when administered alone or in combination (esp. the latter), could up-regulate the LXR expression.